Alnylam Pharmaceuticals Inc.

11/09/2019 | Press release | Distributed by Public on 11/09/2019 11:27

Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label[...]